AltheaDx, a molecular diagnostics firm, has filed for an IPO. The number of shares that will be sold as well as the stock’s pricing terms have yet to be set. AltheaDx plans on listing its stock on the NASDAQ under the ticker symbol “IDGX.” Citigroup and Jefferies are the lead underwriters. AltheaDx’s backers include Telegraph Hill Partners.
SAN DIEGO, Dec. 23, 2014 (GLOBE NEWSWIRE) — AltheaDx, Inc., a commercial stage molecular diagnostics company specializing in the field of personalized medicine, today announced that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission (“SEC”) relating to the proposed initial public offering of its common stock. All of the shares to be sold in the proposed offering will be offered by AltheaDx. The number of shares to be offered and the price range for the proposed offering have not yet been determined. AltheaDx has applied for a listing of its common stock on the NASDAQ Global Market under the ticker symbol “IDGX.”
Citigroup and Jefferies are acting as joint book-running managers of the proposed offering. William Blair and Cantor Fitzgerald & Co. are acting as co-managers.
A registration statement relating to these securities has been filed with the SEC, but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time that the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
The offering will be made only by means of a prospectus. Copies of the preliminary prospectus related to the offering may be obtained, when available, from Citigroup, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by email at email@example.com or by phone at 800-831-9146 and Jefferies, Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by email at Prospectus_Department@Jefferies.com or by phone at 877-547-6340.